Gliclazide modified release

Drugs

Volumn 62, Issue 9, 2002, Pages 1357-1364

  McGavin, Jane K ^a   Perry, Caroline M ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; POTASSIUM CHANNEL;

AGED; ARTHRALGIA; ARTHRITIS; BACKACHE; BRONCHITIS; CLINICAL TRIAL; DIABETIC DIET; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYDROPHILICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SUSTAINED DRUG RELEASE; SYMPTOM;

EID: 0036078915     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262090-00010     Document Type: Review

References (38)

1. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Third National Health and Nutrition Examination Survey, 1988-1994
2. Type 2 diabetes mellitus: The challenge of a metabolic epidemic
3. 1998 Clinical practice guidelines for the management of diabetes in Canada
4. Strategies for better diabetes control in the US
5. Study rationale and design of Advance: Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation
6. A desktop guide to Type 2 diabetes mellitus
7. Standards of medical care for patients with diabetes mellitus
8. Improving the adverse cardiovascular prognosis of type 2 diabetes
9. Gliclazide modified release: From once-daily administration to 24-hour blood glucose control
10. (ATP) channels to gliclazide
11. Glucose modulates the amount, but not the kinetics, of insulin released by sulfonylureas
12. Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: In vitro effects on pancreatic A- and B-cell function
13. Gliclazide treatment of streptozotocin diabetic rats restores GLUT4 protein content and basal glucose uptake in skeletal muscle
14. 24-Hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily
15. Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells
16. (ATP) channels
17. Structural basis for the interference between nicorandil and sulfonylurea action
18. ATP channel openers in the rat and guinea-pig isolated aorta and the hamster cheek pouch
19. Gliclazide scavenges hydroxyl and superoxide radicals: An electron spin resonance study
20. Gliclazide: A general free radical scavenger
21. In vitro and in vivo antioxidant properties of gliclazide
22. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro
23. Gliclazide decreases vascular smooth muscle cell dysfunction induced by cell-mediated oxidized low-density lipoprotein
24. Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels
25. Correction of glycosylated oxyhemoglobin-induced impairment of endothelium-dependent vasodilatation by gliclazide
26. Prevention of endothelial dysfunction in streptozotocin-induced diabetic rats by gliclazide treatment
27. Gliclazide reduces the induction of human monocyte adhesion to endothelial cells by glycated albumin
28. Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL
29. Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: Effect of antidiabetic medicines
30. Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide
31. Complete bioavailability and lack of food-effect on pharmacokinetics of glicazide 30 mg modified release in healthy volunteers
32. Pharmacokinetics of Diamicron modified release (MR) in 1007 type 2 diabetic patients
33. Effect of gliclazide in a new once-a-day formulation
34. The mode of action and clinical pharmacology of glicazide: A review
35. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: A double-blind, randomised, multinational study
36. Two year efficacy and safety of Diamicron MR in inadequately controlled patients with type 2 diabetes
37. Two year efficacy and safety of Diamicron® MR in inadequately controlled patients with type 2 diabetes